Provided by Tiger Trade Technology Pte. Ltd.

Aprea Therapeutics, Inc.

0.6900
+0.065610.51%
Post-market: 0.6505-0.0395-5.72%19:32 EST
Volume:525.39K
Turnover:332.04K
Market Cap:4.83M
PE:-0.32
High:0.6900
Open:0.6149
Low:0.5862
Close:0.6244
52wk High:4.10
52wk Low:0.5480
Shares:6.99M
Float Shares:4.56M
Volume Ratio:0.02
T/O Rate:11.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1364
EPS(LYR):-2.3519
ROE:-74.72%
ROA:-41.90%
PB:0.44
PE(LYR):-0.29

Loading ...

Aprea Therapeutics Names Eugene Kennedy as Chief Medical Advisor

Reuters
·
Feb 04

Aprea Therapeutics Inc. President and CEO Gilad Oren Reports Acquisition of Common Shares

Reuters
·
Feb 03

Aprea Therapeutics CFO John P. Hamill Acquires Common Shares

Reuters
·
Feb 03

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:52 AM

Reuters
·
Jan 31

Aprea Therapeutics prices 6.29M shares at 89c in private placement

TIPRANKS
·
Jan 29

Aprea Therapeutics announces early PoC data in ACESOT-1051 trial

TIPRANKS
·
Jan 29

Aprea Therapeutics Reports Early Proof-of-Concept for WEE1 Inhibitor APR-1051 in Solid Tumors

Reuters
·
Jan 29

Aprea Therapeutics Inc - 50% Reduction in Lesion, 90% Decrease in CA-125 in Patient

THOMSON REUTERS
·
Jan 29

Aprea Therapeutics Announces Early Clinical Proof-of-Concept in the Ongoing Acesot-1051 Dose-Escalation Trial Evaluating Wee1 Inhibitor Apr-1051, Including Partial Response Observed on First Scan

THOMSON REUTERS
·
Jan 29

Aprea Therapeutics Inc - Unconfirmed Partial Response at 150 Mg Dose

THOMSON REUTERS
·
Jan 29

Aprea Therapeutics Inc: Additional Updates in First Half of 2026 and Completing Dose Escalation Later in Year

THOMSON REUTERS
·
Jan 29

Aprea Therapeutics Announces $5.6 Million Private Placement Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
Jan 29

Aprea Therapeutics Faces Nasdaq Delisting Risk Over Minimum Bid Price

Reuters
·
Jan 26

U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart

Reuters
·
Dec 22, 2025

Aprea Therapeutics Inc - Files Prospectus for Resale of 5.5 Mln Shares by the Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Dec 20, 2025

Aprea Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $5 From $20

THOMSON REUTERS
·
Dec 19, 2025

BRIEF-Aprea Therapeutics CEO Issues Letter To Shareholders Highlighting Outlook For 2026

Reuters
·
Dec 18, 2025

Aprea Therapeutics Inc - Pauses Enrollment in Aboya-119 Study Monotherapy Arms

THOMSON REUTERS
·
Dec 18, 2025

Director Marc Duey Reports Acquisition of Common Shares in Aprea Therapeutics Inc

Reuters
·
Dec 11, 2025

Aprea Therapeutics CFO John P. Hamill Reports Acquisition of Common Shares

Reuters
·
Dec 11, 2025